Global Health 2013: Rise of the resistance
Science Capital offer discounted rates to Lunar Society Members
Wednesday 13 November from 5:30-10pm at Hotel du Vin Birmingham, Church Street, B3 2NR
Website: http://www.sciencecapital.co.uk/2013-global-health Organiser: Science Capital
Theme & background: This event is offered in partnership with The Lunar Society, and gives participants the opportunity to discuss the latest developments for combating pathogens including viruses, bacteria, and fungi. Participants are invited to build new connections at a time when open innovation, collaboration and partnership are increasing vital for development of new treatments for drug resistance strains and systems to track and limit the spread of infectious diseases. We will focus on exploring how academics, clinicians, biotech and pharmaceutical companies can work together and explore new opportunities for moving the field forwards in the region and beyond.
Earlybird tickets cost £29 (Academic/SME) and include reception, dinner and networking session.
Jason Clark Chief Technology Officer of Novolytics will present on utilising nature’s own natural antidote, bacteriophages, to treat contagious bacteria. He obtained a PhD in microbiology from the University of Edinburgh, and founded BigDNA Limited. Novolytics is a spin-out from the University of Warwick, and has partnered with Cobra Biologics Ltd to capitalise on their recent breakthrough in the development of phage products for “superbugs” including MRSA.
Mark Pallen is Professor of Microbial Genomics at the University of Warwick, and aims to understand bacterial pathogens and complex microbial communities in order to improve human health and well-being. His team sequences the genomes of microbes, and develops tools to tackle those that contaminate the food chain or represent emerging threats due to bioterrorism and the spread of hospital pathogens and multi-drug resistance.
Peter Lambert is the Professor of Microbial Chemistry at Aston University, and specialises in the diagnosis and treatment of infectious diseases, bacterial adhesion and colonisation, and the mechanisms of antibiotics and resistance. He will present “germinate exterminate”, a strategy that uses specific agents to trigger germination of spores of C. difficile, allowing effective decontamination in healthcare settings.
Participants are welcome to present their business plans and ideas to a panel of advisors in the afternoon. Selected legal, business, financial and investment advisors who are experienced in developing commercialisation strategies will provide friendly and supportive advice. Pro-bono support is available to presenters from firms including FD Solutions, Quarto Perspective, Wragge & Co and HGF.